Plus Therapeutics (PSTV) Short term Debt (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Short term Debt data on file, last reported at $667000.0 in Q1 2026.

• Short term Debt for Q1 2026 came in at $667000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $667000.0 (changed N/A YoY), and the FY2025 annual result was $750000.0, down 77.22% from the prior year.
• Short term Debt fell to $667000.0 in Q1 2026 per PSTV's latest filing, from $750000.0 in the prior quarter.
• Over five years, Short term Debt peaked at $5.1 million in Q1 2023 and troughed at $667000.0 in Q1 2026.
• A 5-year average of $2.8 million and a median of $3.3 million in 2024 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2023 and 2025: Short term Debt jumped 214.49% in 2023, then slumped 77.22% in 2025.
• A 5-year view of Short term Debt shows it stood at $1.6 million in 2022, then jumped by 147.26% to $4.0 million in 2023, then declined by 17.2% to $3.3 million in 2024, then tumbled by 77.22% to $750000.0 in 2025, then slipped by 11.07% to $667000.0 in 2026.
• Business Quant data shows PSTV's Short term Debt at $667000.0 in Q1 2026, $750000.0 in Q4 2025, and $3.3 million in Q4 2024.